secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001867096-22-000123
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma Q3 product revenue $29.6M, record; raises cash guidance to $110-120M
--------------------------------------------------------------------------------

- Net product revenue $29.6M, up 31% pro forma YoY; Gvoke $13.7M (+24%), Keveyis $13.4M, Recorlev $2.5M.
- Full-year net product revenue guidance tightened to $105-110M; year-end cash guidance raised to $110-120M.
- Net loss $21.8M ($0.16/share) for Q3; cash & investments $93.4M at Sept 30.
- Positive Phase 1 topline for subcutaneous levothyroxine (XP-8121); FDA Type C meeting requested.
- On track for $50M in synergies by year-end 2022 and cash flow breakeven by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000123/0001867096-22-000123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000123/xers-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001867096-22-000123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer